WEEKLY NEWS

Stock and Market News

ARTIFICIAL INTELLIGENCE
🌎 AI News

  • Anthropic opens talks with Washington: Anthropic said it is in discussions with the Trump administration about its new Mythos model, even after the Pentagon blacklisted the company over a military contract dispute tied to usage guardrails. Reuters

  • Meta launches Muse Spark: Meta unveiled Muse Spark, the first model from its new superintelligence team, as it tries to regain momentum in the AI race after a lukewarm response to Llama 4. Meta

  • AI infrastructure demand stays red-hot: CoreWeave signed a multi-year deal to provide Anthropic with cloud computing capacity for Claude workloads, another sign that large-model infrastructure spending is still accelerating. Reuters

  • OpenAI faces valuation scrutiny: Reuters reported on April 14 that some OpenAI investors are questioning the company’s reported $852 billion valuation as strategy shifts ripple through the business. Reuters

  • The cost of frontier AI keeps climbing: The Wall Street Journal reported that OpenAI and Anthropic expect to spend nearly $65 billion combined in 2026 just to train and run their models, underscoring how capital-intensive the race has become. WSJ

  • AI chip startup DeepX prepares to go public: Reuters reported on April 14 that South Korea’s DeepX is preparing an IPO as investor appetite for AI infrastructure and semiconductor plays remains strong. Reuters

Economic News
Econ Calendar

  • Producer prices are the big U.S. data point this week: March PPI is expected to rise 1.2% month over month, with core PPI seen up 0.5%, giving investors an early read on how much of the recent energy shock is flowing into producer costs. Trading Economics (Trading Economics)

  • Industrial production is also on deck: U.S. industrial production for March is expected to slow to 0.1% growth, a softer pace that would suggest manufacturing momentum remains modest. Trading Economics (Trading Economics)

  • Housing data will test demand: Existing home sales are expected to ease to 4.01 million from 4.09 million in February, keeping the spotlight on affordability and housing turnover. Trading Economics (Trading Economics)

  • Fed speakers are back in focus: Several Federal Reserve officials are scheduled to speak this week after March CPI showed inflation climbing to a two-year high, giving markets another chance to recalibrate rate expectations. Trading Economics (Trading Economics)

  • China’s data dump could move global markets: China is due to report Q1 GDP, trade, industrial production, retail sales, unemployment, housing prices, and credit data this week. Reuters’ poll expects Q1 GDP growth of 4.8%, up from 4.5% in Q4, though the Iran war is clouding the outlook. Reuters (Reuters)

  • The macro backdrop still runs through oil and geopolitics: Reuters says markets are watching whether Middle East tensions keep oil elevated, while upcoming U.S. producer-price data and Fed commentary are the next scheduled tests for inflation and risk assets. Reuters (Reuters)

  • IMF and World Bank spring meetings begin this week: The meetings add another macro focal point as investors look for updated growth, inflation, and policy commentary from global officials. Trading Economics (Trading Economics)

A stronger section title than “Economic Calendar news” would be Economic Calendar or On the Calendar.

Daily Analyst
Beats and Raises

  • Syre - Spyre Therapeutics - 7 Analyst Revisions (!) new target $98-$107

    • SYRE reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY001

  • IDYA - IDEAYA Biosciences - 2 revisions with many this last month

    • IDEAYA and Servier said darovasertib + Xalkori met the primary endpoint in a mid-to-late-stage trial in uveal melanoma, with median progression-free survival of 6.9 months vs. 3.1 months for investigator-chosen therapy

  • Aly - Ally Financial

    • Earnings beats last week with 5 analyst revisions targeting $50 from $41.

Stocks
Stock Picks

Killer Compounders

  • META

  • NVDA

  • ALLY

  • AVGO

  • SPGI

  • MSCI

  • CME

  • NDAQ

  • ICE

  • LLY

  • ASML

  • CBOE

  • MCO

Target Upside over 30%:

  • PARR

  • AVGO

  • SPGI

  • MSCI

  • IDYA

  • CME

  • NDAQ

  • MELI

  • XENE

  • ASND

  • LLY

  • IBKR

  • ICE

  • CBOE

  • MCO

  • BSX

We will go through these stocks throughout the month to reiterate why buy.

-talk soon,

Chris

Keep Reading